SKI-606, an Src Inhibitor, Reduces Tumor Growth, Invasion, and Distant Metastasis in a Mouse Model of Thyroid Cancer

Overview

Journal Clin Cancer Res

Specialty Oncology

Date 2012 Jan 25

PMID 22271876

Citations 28

Authors

Won Gu Kim

Celine J Guigon

Laura Fozzatti

Jeong Won Park

Changxue Lu

Mark C Willingham

Sheue-Yann Cheng

Affiliations

Soon will be listed here.

Abstract

Purpose: Src is overexpressed or hyperactivated in a variety of human cancers, including thyroid carcinoma. Src is a central mediator in multiple signaling pathways that are important in oncogenesis and cancer progression. In this study, we evaluated the effects of an Src inhibitor, SKI-606 (bosutinib), in a spontaneous metastatic thyroid cancer model with constitutively activated Src (Thrb(PV/PV)Pten(+/-) mice).

Experimental Design: Thrb(PV/PV)Pten(+/-) mice were treated with SKI-606 or vehicle controls, beginning at 6 weeks of age until the mice succumbed to thyroid cancer. We assessed the effects of SKI-606 on thyroid cancer progression and analyzed the impact of SKI-606 on aberrant Src-mediated signaling.

Results: SKI-606 effectively inhibited aberrant activation of Src and its downstream targets to markedly inhibit the growth of thyroid tumor, thereby prolonging the survival of treated mice. While Src inhibition did not induce cell apoptosis, it decreased cell proliferation by affecting the expression of key regulators of cell-cycle progression. Importantly, SKI-606 dramatically prevented dedifferentiation, vascular invasion, and lung metastasis of thyroid cancer cells. These responses were meditated by downregulation of mitogen-activated protein kinase pathways and inhibition of the epithelial-mesenchymal transition.

Conclusions: Our findings suggest that Src is critical in the progression of thyroid cancer, making oral SKI-606 a promising treatment strategy for refractory thyroid cancer.

Citing Articles

Prophylactic central neck dissection for cN0 papillary thyroid carcinoma: is there any difference between western countries and China? A systematic review and meta-analysis.

Yang J, Han Y, Min Y, Chen C, Chen J, Xiang K Front Endocrinol (Lausanne). 2023; 14:1176512.

PMID: 37576962 PMC: 10413573. DOI: 10.3389/fendo.2023.1176512.

Pan-cancer Analysis Reveals SRC May Link Lipid Metabolism and Macrophages.

Chen Z, Xiao Y, Yang P, Wang R Iran J Biotechnol. 2023; 21(2):e3325.

PMID: 37228626 PMC: 10203188. DOI: 10.30498/ijb.2023.335402.3325.

Targeted therapy for head and neck cancer: signaling pathways and clinical studies.

Li Q, Tie Y, Alu A, Ma X, Shi H Signal Transduct Target Ther. 2023; 8(1):31.

PMID: 36646686 PMC: 9842704. DOI: 10.1038/s41392-022-01297-0.

Role of succinylation modification in thyroid cancer and breast cancer.

Mu R, Ma Z, Lu C, Wang H, Cheng X, Tuo B Am J Cancer Res. 2021; 11(10):4683-4699.

PMID: 34765287 PMC: 8569371.

Therapeutic Targeting of the Gas6/Axl Signaling Pathway in Cancer.

Tanaka M, Siemann D Int J Mol Sci. 2021; 22(18).

PMID: 34576116 PMC: 8469858. DOI: 10.3390/ijms22189953.

References

Owens L, Xu L, Dent G, Yang X, Sturge G, Craven R . Focal adhesion kinase as a marker of invasive potential in differentiated human thyroid cancer. Ann Surg Oncol. 1996; 3(1):100-5. DOI: 10.1007/BF02409059. View

Guarino M . Src signaling in cancer invasion. J Cell Physiol. 2010; 223(1):14-26. DOI: 10.1002/jcp.22011. View

Ying H, Suzuki H, Furumoto H, Walker R, Meltzer P, Willingham M . Alterations in genomic profiles during tumor progression in a mouse model of follicular thyroid carcinoma. Carcinogenesis. 2003; 24(9):1467-79. DOI: 10.1093/carcin/bgg111. View

Jallal H, Valentino M, Chen G, Boschelli F, Ali S, Rabbani S . A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo. Cancer Res. 2007; 67(4):1580-8. DOI: 10.1158/0008-5472.CAN-06-2027. View

Sherman S . Targeted therapies for thyroid tumors. Mod Pathol. 2011; 24 Suppl 2:S44-52. DOI: 10.1038/modpathol.2010.165. View

Kim C, Vasko V, Kato Y, Kruhlak M, Saji M, Cheng S . AKT activation promotes metastasis in a mouse model of follicular thyroid carcinoma. Endocrinology. 2005; 146(10):4456-63. DOI: 10.1210/en.2005-0172. View

Kim S, Park J, Yoon J, Mok J, Kim Y, Park H . Increased expression of focal adhesion kinase in thyroid cancer: immunohistochemical study. J Korean Med Sci. 2004; 19(5):710-5. PMC: 2816336. DOI: 10.3346/jkms.2004.19.5.710. View

Furumoto H, Ying H, Chandramouli G, Zhao L, Walker R, Meltzer P . An unliganded thyroid hormone beta receptor activates the cyclin D1/cyclin-dependent kinase/retinoblastoma/E2F pathway and induces pituitary tumorigenesis. Mol Cell Biol. 2004; 25(1):124-35. PMC: 538780. DOI: 10.1128/MCB.25.1.124-135.2005. View

Rini B, Tamaskar I, Shaheen P, Salas R, Garcia J, Wood L . Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst. 2007; 99(1):81-3. DOI: 10.1093/jnci/djk008. View

10.

Hsia D, Mitra S, Hauck C, Streblow D, Nelson J, Ilic D . Differential regulation of cell motility and invasion by FAK. J Cell Biol. 2003; 160(5):753-67. PMC: 2173366. DOI: 10.1083/jcb.200212114. View

11.

Lu C, Zhao L, Ying H, Willingham M, Cheng S . Growth activation alone is not sufficient to cause metastatic thyroid cancer in a mouse model of follicular thyroid carcinoma. Endocrinology. 2010; 151(4):1929-39. PMC: 2851190. DOI: 10.1210/en.2009-1017. View

12.

Vultur A, Buettner R, Kowolik C, Liang W, Smith D, Boschelli F . SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells. Mol Cancer Ther. 2008; 7(5):1185-94. PMC: 2794837. DOI: 10.1158/1535-7163.MCT-08-0126. View

13.

Kim L, Song L, Haura E . Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol. 2009; 6(10):587-95. DOI: 10.1038/nrclinonc.2009.129. View

14.

Meng X, Jin Y, Yu Y, Bai J, Liu G, Zhu J . Characterisation of fibronectin-mediated FAK signalling pathways in lung cancer cell migration and invasion. Br J Cancer. 2009; 101(2):327-34. PMC: 2720209. DOI: 10.1038/sj.bjc.6605154. View

15.

Kilfoy B, Zheng T, Holford T, Han X, Ward M, Sjodin A . International patterns and trends in thyroid cancer incidence, 1973-2002. Cancer Causes Control. 2008; 20(5):525-31. PMC: 2788231. DOI: 10.1007/s10552-008-9260-4. View

16.

Pearson G, Robinson F, Beers Gibson T, Xu B, Karandikar M, Berman K . Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev. 2001; 22(2):153-83. DOI: 10.1210/edrv.22.2.0428. View

17.

Brecelj E, Frkovic Grazio S, Auersperg M, Bracko M . Prognostic value of E-cadherin expression in thyroid follicular carcinoma. Eur J Surg Oncol. 2005; 31(5):544-8. DOI: 10.1016/j.ejso.2005.02.003. View

18.

Scheumman G, Hoang-Vu C, Cetin Y, Gimm O, Behrends J, von Wasielewski R . Clinical significance of E-cadherin as a prognostic marker in thyroid carcinomas. J Clin Endocrinol Metab. 1995; 80(7):2168-72. DOI: 10.1210/jcem.80.7.7608273. View

19.

Golas J, Arndt K, Etienne C, Lucas J, Nardin D, Gibbons J . SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res. 2003; 63(2):375-81. View

20.

Coluccia A, Benati D, Dekhil H, De Filippo A, Lan C, Gambacorti-Passerini C . SKI-606 decreases growth and motility of colorectal cancer cells by preventing pp60(c-Src)-dependent tyrosine phosphorylation of beta-catenin and its nuclear signaling. Cancer Res. 2006; 66(4):2279-86. DOI: 10.1158/0008-5472.CAN-05-2057. View